SLE patient demographics. Values are % unless otherwise specified.
| Characteristics | Danish | Swiss |
|---|---|---|
| No. patients | 372 | 52 |
| Age at inclusion, yrs, mean (SD) | 46.7 (14.6) | 42 (13) |
| Age at diagnosis, yrs, mean (SD) | 34.8 (14.5) | 32 (11) |
| Female sex | 88 | 84 |
| Ethnicity: white | 97 | 90 |
| ACR criteria (cumulative) | ||
| No. ACR criteria, mean (SD) | 5.9 (1.5) | 5.4 (1.2) |
| Malar rash (ACR1) | 57.5 | 50.0 |
| Discoid lupus (ACR2) | 5.4 | 4.8 |
| Photosensitivity (ACR3) | 63.0 | 23.8 |
| Oral/nasal ulcers (ACR4) | 33.2 | 26.2 |
| Arthritis (ACR5) | 88.7 | 90.5 |
| Serositis (ACR6) | 39.1 | 23.8 |
| Nephritis (ACR7) | 33.9 | 59.5 |
| CNS (ACR8) | 12.7 | 9.5 |
| Hematological (ACR9) | 71.2 | 71.4 |
| Immunological (ACR10) | 87.9 | 88.1 |
| ANA (ACR11) | 99.2 | 92.9 |
| Clinical and biochemical data at time of inclusion | ||
| SLEDAI at inclusion, mean (SD) | 3.1 (3.07) | 4.5 (4.5) |
| SLICC, mean (SD) | 1.3 (2.34) | NA |
| Proteinurea > 0.5 g/day | 8.3 | 11.9 |
| Antiphospholipid syndrome | 28.5 | NA |
| Treatment at time of inclusion | ||
| Hydroxychloroquine treatment | 62.5 | 85.7 |
| Prednisolone treatment | 54.2 | 50.0 |
| Other immunosuppressives* | 42.5 | 47.6 |
↵* Includes methotrexate, azathioprine, mycophenolate, rituximab, belimumab, cyclophosphamide, and tacrolimus. SLE: systemic lupus erythematosus; ACR: American College of Rheumatology; CNS: central nervous system; ANA: antinuclear antibody; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics; NA: not applicable.